Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
Holding ETNB?
Track your performance easily
ETNB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.58 - $17.33
Previous Close$8.35
Volume153.20K
Average Volume (3M)804.41K
Market Cap
$904.47M
Enterprise Value$380.31M
Total Cash (Recent Filing)$531.38M
Total Debt (Recent Filing)$27.35M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 07, 2024EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding105,909,991
10 Day Avg. Volume441,700
30 Day Avg. Volume804,414
Standard Deviation0.25
R-Squared0.05
Alpha-0.00105
Financial Highlights & Ratios
Price to Book (P/B)1.72
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$27.00Price Target Upside216.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
89bio News
PremiumCompany Announcements
89bio Welcomes New COO Francis Sarena with Robust Compensation
Bulls Say, Bears Say
Bulls Say
Clinical DataPatients treated with pegozafermin showed statistically significant improvements across key liver health markers at Week 48.
Market ResearchETNB presented encouraging new market research of pegoza's commercial opportunity, if approved.
Ongoing TrialsThe initiation of the Phase 3 ENLIGHTEN-Cirrhosis study is considered a major achievement.
Bears Say
Clinical TrialsRisks include potential clinical trial failure and challenges in securing regulatory approvals.
CompetitionConcerns over competition in the fatty liver disease space and commercial unknowns ahead of the first-to-market MASH launch have weighed sentiment.
Market SentimentConcerns over competition in the fatty liver disease space and commercial unknowns ahead of the first-to-market MASH launch have weighed sentiment.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $6.58 and its highest was $17.33 in the past 12 months.
What is 89bio’s market cap?
Currently, no data Available
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is Nov 07, 2024 which is in 50 days.
How were 89bio’s earnings last quarter?
89bio released its earnings results on Aug 05, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.564 by $0.084.
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate is -$0.62.
How many shares outstanding does 89bio have?
89bio has 105,909,990 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
89bio reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.564. Following the earnings report the stock price went down -5.364%.
Which hedge fund is a major shareholder of 89bio?
Among the largest hedge funds holding 89bio’s share is RA Capital Management. It holds 89bio’s shares valued at 114M.
---
89bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.00 (216.16% Upside)
$27.00 (216.16% Upside)
Blogger Sentiment
Bullish
ETNB Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.90%
12-Months-Change
Fundamentals
Return on Equity
-36.50%
Trailing 12-Months
Asset Growth
18.20%
Trailing 12-Months
Company Description
89bio
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
---
ETNB Stock 12 Month Forecast
Average Price Target
$27.00
▲(216.16% Upside)
Technical Analysis
Viking Therapeutics
―
Madrigal Pharmaceuticals
―
Akero Therapeutics
―
Apellis Pharmaceuticals
―
Best Analysts Covering ETNB
1 Year
1 Year Success Rate
10/23 ratings generated profit
1 Year Average Return
+60.02%
reiterated a buy rating last month
Copying Thomas Smith's trades and holding each position for 1 Year would result in 43.48% of your transactions generating a profit, with an average return of +60.02% per trade.
---